USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Plasma Thermograms for Disease Detection and Monitoring

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
91077
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
0912660
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Louisville Bioscience, Inc.
400 W Market St, Ste 1800 Louisville, KY 40202 3362
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: SBIR Phase I: Plasma Thermograms for Disease Detection and Monitoring
Agency: NSF
Contract: 0912660
Award Amount: $99,801.00
 

Abstract:

This Small Business Innovation Research Phase I project is to develop and commercialize a powerful new diagnostic assay platform for quantitative analysis of plasma from human blood using Differential Scanning Calorimetry. The platform will form the basis for generating novel high-throughput diagnostic assays requiring minimal sample handling and processing that can be performed in an hour on a single drop of blood. Output is in the form of a melting curve, or thermogram. Each thermogram provides a highly sensitive and specific signature for a variety of disease states including various cancers, auto-immune and infectious diseases. Thermograms establish a powerful new vista from which to view plasma diagnostics and provide an excellent complement to more traditional plasma diagnostic methods (electrophoresis and mass spectrometry) that separate plasma/serum proteins based on their mass and charge. The broader impacts of this research stem from the multiplicity of applications provided by the platform to be developed. These applications include: (1) Early stage disease detection, (2) Distinction between different stages of disease, remission and relapse (disease progression), (3) Assessing effects of therapeutic regimens and therapeutic monitoring, and (4) Identification of therapeutic targets for drug development (i.e. biomarker discovery). The universal platform provided by the plasma thermogram technology allows for the capability of detecting, diagnosing and monitoring a variety of very important diseases with high, unmet medical needs. This provides a multi-billion dollar opportunity for the commercialized plasma thermogram technology platform and diagnostic assays. This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).

Principal Investigator:

Greg P. Brewood
DPhil
5037252350
gbrewood@pdxbio.com

Business Contact:

Greg P. Brewood
DPhil
5037252350
gbrewood@pdxbio.com
Small Business Information at Submission:

Louisville Bioscience, Inc.
400 W Market St, Ste 1800 Louisville, KY 40202

EIN/Tax ID: 262305988
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No